Promarker D Promarker D, developed by Proteomics, is a predictive screening tool. While yet to be approved by the Therapeutic Goods Administration, it offers an insight into the growing ability to use blood checks as a preventive diagnostic. It claims the ability to predict the development of diabetic kidney disease up to four years in advance, allowing people the chance to act on medications and lifestyle changes earlier, diminishing the extent of kidney damage. Promarker D is conducted through a routine blood check which is sent to a laboratory for analysis, with results returned to the health professional.
Above you find the part where Promarker D is mentioned in the article
Ann: Sonic Healthcare USA signs licence for PromarkerD in the US, page-50
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $124.3M | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 94.0¢ | $53.2K | 56.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 157000 | 2 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
95.5¢ |
Change
0.000 ( 0.53 %) |
||||
| Open | High | Low | Volume | ||
| 95.0¢ | 95.5¢ | 95.0¢ | 3157 | ||
| Last updated 15.46pm 07/06/2024 ? | |||||
| PIQ (ASX) Chart |